Search
Dezocine
go.drugbank.com/drugs/DB01209ApprovedInvestigationalDezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeCorticotropin
go.drugbank.com/drugs/DB01285ApprovedInvestigationalVet approvedCorticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.
Clobetasol propionate
go.drugbank.com/drugs/DB01013ApprovedInvestigational[A190936] Clobetasol Propionate was granted FDA approval on 27 December 1985.[L11809] … [L11815] It has demonstrated superior activity compared to [fluocinonide][A190963] and was first described in the literature in 1974.
Cyclopentolate
go.drugbank.com/drugs/DB00979ApprovedA parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia.
Norelgestromin
go.drugbank.com/drugs/DB06713ApprovedInvestigational[L63816] Combined hormonal contraceptives containing norelgestromin lower the risk of pregnancy primarily by suppressing ovulation.
Mixtures: Gwyn LoEnfortumab vedotin
go.drugbank.com/drugs/DB13007ApprovedInvestigational[L10836] Enfortumab vedotin was later approved by the European Commission on April 13, 2022.[L42000] … [L10836] It is similar to [brentuximab vedotin], another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4.
Pirfenidone
go.drugbank.com/drugs/DB04951ApprovedInvestigational[A251370] While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necrosis factor (TNF) pathways and modulate cellular oxidation. … [A251365] The FDA first approved pirfenidone alongside [nintedanib] as one of the first drugs to treat IPF.[A251165]
Categories: Analgesics, Non-NarcoticErdafitinib
go.drugbank.com/drugs/DB12147ApprovedInvestigationalpersonalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the development of more personalized and precise medicines tailoring to … Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic tool kit to
Dotatate gallium Ga-68
go.drugbank.com/drugs/DB13925ApprovedInvestigationalWithdrawn[A31358] Dotatate gallium 68 was developed by Advanced Accelerator Applications USA, Inc. and FDA approved in June 1, 2016. … Dotatate gallium (Ga-68) explotes its ability to detect somatostatin receptor scintigraphy and this characteristic tends to change with tumor grade which gives Ga-68 dotate a high diagnostic value.
Givinostat
go.drugbank.com/drugs/DB12645ApprovedInvestigationalIn the context of muscular dystrophy, inhibitors of HDAC appear to exert their therapeutic effects by targeting pathogenic processes that cause inflammation and muscle loss. … [L50311,L50316] It is the first non-steroidal drug approved to treat patients with all genetic variants of DMD.[L50316]